Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) Other Non Operating Income (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Other Non Operating Income for 3 consecutive years, with $5.6 million as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income fell 84.95% to $5.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.3 million through Dec 2025, down 17.04% year-over-year, with the annual reading at $13.1 million for FY2025, 66.16% down from the prior year.
  • Other Non Operating Income hit $5.6 million in Q4 2025 for NewAmsterdam Pharma, down from $23.8 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $37.3 million in Q4 2024 to a low of -$13.8 million in Q1 2025.
  • Historically, Other Non Operating Income has averaged $5.3 million across 3 years, with a median of $1.5 million in 2023.
  • Biggest five-year swings in Other Non Operating Income: plummeted 1280.56% in 2024 and later skyrocketed 967.81% in 2025.
  • Year by year, Other Non Operating Income stood at $10.2 million in 2023, then skyrocketed by 266.6% to $37.3 million in 2024, then tumbled by 84.95% to $5.6 million in 2025.
  • Business Quant data shows Other Non Operating Income for NAMS at $5.6 million in Q4 2025, $23.8 million in Q3 2025, and $8.6 million in Q2 2025.